Overview

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-072 and ribavirin (RBV) in treatment-naïve participants with genotype 1 chronic hepatitis C virus (HCV) infection.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Antiviral Agents
Ribavirin
Ritonavir